26,670 Shares in DexCom, Inc. $DXCM Purchased by SBI Okasan Asset Management Co.Ltd.

SBI Okasan Asset Management Co.Ltd. purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the fourth quarter, Holdings Channel.com reports. The firm purchased 26,670 shares of the medical device company’s stock, valued at approximately $1,799,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares in the last quarter. ORG Partners LLC lifted its position in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares in the last quarter. Spire Wealth Management lifted its position in shares of DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares in the last quarter. Aventura Private Wealth LLC purchased a new stake in shares of DexCom in the fourth quarter worth approximately $43,000. Finally, Rothschild Investment LLC lifted its position in shares of DexCom by 59.9% in the third quarter. Rothschild Investment LLC now owns 654 shares of the medical device company’s stock worth $44,000 after purchasing an additional 245 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the transaction, the executive vice president directly owned 111,204 shares in the company, valued at $7,010,300.16. The trade was a 1.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at approximately $27,538,704. This trade represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,871 shares of company stock worth $2,306,638 over the last 90 days. Insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on DXCM shares. Robert W. Baird set a $80.00 price target on shares of DexCom in a research report on Friday, May 1st. Truist Financial reissued a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a research report on Friday, May 1st. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Finally, Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, May 18th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.42.

DexCom Trading Up 3.0%

Shares of DXCM stock opened at $72.34 on Friday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average is $64.05 and its two-hundred day moving average is $66.39. The company has a market cap of $27.91 billion, a PE ratio of 30.91, a price-to-earnings-growth ratio of 1.16 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the company posted $0.32 earnings per share. The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. Equities analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.